DSCAM-AS1, AJCC stage, differentiation, lymph node metastasis, and PSA have the potential to serve as prognostic bioindicators for prostate cancer patients. The gene discussed is DSCAM; the disease is metastatic malignant neoplasm in the lymph nodes.